LY-CoV555, a neutralizing monoclonal antibody, has been associated with a decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients with coronavirus ...

Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533 Vaccine-induced nAbs are detectable at much lower rates ...

Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern pose a challenge to the effectiveness of current vaccines. A vaccine that could prevent infection caused by ...

From the start of the COVID-19 pandemic, many of researchers’ nagging questions involved trying to understand what constitutes immunity to future infections. People who had been infected by the virus ...

It has been one year since the outbreak of COVID-19, but there is still an increasing number of confirmed cases. The epidemic situation is still challenged all over the world. The effective drug ...

How could we forget the SARS-CoV-2 pandemic, right? It’s now part of our history, a story to pass on to the next generation. There are hundreds of related SARS-CoV strains known to infect different ...

Antibodies have become an integral part of research and medicine. Therapeutic applications of antibodies began to emerge following the publication of Köhler and Milstein’s groundbreaking 1975 paper in ...